IRWD vs. IGMS, KURA, CYRX, ZNTL, BHC, FOLD, CLDX, GERN, MYGN, and NVAX
Should you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include IGM Biosciences (IGMS), Kura Oncology (KURA), Cryoport (CYRX), Zentalis Pharmaceuticals (ZNTL), Bausch Health Companies (BHC), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Geron (GERN), Myriad Genetics (MYGN), and Novavax (NVAX).
IGM Biosciences (NASDAQ:IGMS) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends, analyst recommendations and community ranking.
Ironwood Pharmaceuticals received 443 more outperform votes than IGM Biosciences when rated by MarketBeat users. Likewise, 61.11% of users gave Ironwood Pharmaceuticals an outperform vote while only 48.84% of users gave IGM Biosciences an outperform vote.
Ironwood Pharmaceuticals has a net margin of -254.41% compared to Ironwood Pharmaceuticals' net margin of -11,255.25%. IGM Biosciences' return on equity of -28.45% beat Ironwood Pharmaceuticals' return on equity.
IGM Biosciences currently has a consensus price target of $17.89, suggesting a potential upside of 60.01%. Ironwood Pharmaceuticals has a consensus price target of $18.40, suggesting a potential upside of 161.36%. Given IGM Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than IGM Biosciences.
In the previous week, Ironwood Pharmaceuticals had 1 more articles in the media than IGM Biosciences. MarketBeat recorded 7 mentions for Ironwood Pharmaceuticals and 6 mentions for IGM Biosciences. IGM Biosciences' average media sentiment score of 0.91 beat Ironwood Pharmaceuticals' score of 0.60 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.
IGM Biosciences has higher earnings, but lower revenue than Ironwood Pharmaceuticals. IGM Biosciences is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
42.8% of IGM Biosciences shares are owned by institutional investors. 57.0% of IGM Biosciences shares are owned by insiders. Comparatively, 12.9% of Ironwood Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
IGM Biosciences has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.
Summary
Ironwood Pharmaceuticals beats IGM Biosciences on 13 of the 18 factors compared between the two stocks.
Get Ironwood Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ironwood Pharmaceuticals Competitors List
Related Companies and Tools
